Results 81 to 90 of about 76,606 (312)

Literature‐informed ensemble machine learning for three‐year diabetic kidney disease risk prediction in type 2 diabetes: Development, validation, and deployment of the PSMMC NephraRisk model

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Introduction Diabetic kidney disease (DKD) and diabetic nephropathy (DN) affect around 40% of diabetic patients but lack accurate risk prediction tools that include social determinants and demographic complexity. We developed and validated an ensemble machine learning model for three‐year DKD/DN risk prediction with deployment readiness ...
Ayla M. Tourkmani   +5 more
wiley   +1 more source

Long‐acting insulin analogues and the risk of diabetic nephropathy among patients with type 2 diabetes: A population‐based cohort study

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims The risk of diabetic nephropathy among patients with type 2 diabetes (T2D) can be reduced through optimal glycaemic control. It is not known if the pharmacological properties of long‐acting insulin analogues may reduce the risk of diabetic complications compared with neutral protamine Hagedorn (NPH) insulin.
Julia Brillinger   +6 more
wiley   +1 more source

Reduction of microalbuminuria in type-2 diabetes mellitus with angiotensin-converting enzyme inhibitor alone and with cilnidipine

open access: yesIndian Journal of Nephrology, 2015
The aim of our study was to find out the antiproteinuric effect of enalapril angiotensin-converting enzyme (ACE inhibitor) alone or in combination with cilnidipine in patients with type-2 diabetes mellitus.
Vivek Singh   +5 more
semanticscholar   +1 more source

Once‐weekly insulin icodec versus once‐daily insulin degludec for type 2 diabetes in China: A cost‐utility and budget impact analysis

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Insulin icodec, the first once‐weekly basal insulin analogue, was approved in China in 2024. Although it has demonstrated robust clinical efficacy, its budget impact remains unknown, and the long‐term cost‐utility within the reimbursement context needs further estimates.
Xichen Tong   +3 more
wiley   +1 more source

Relationship of Glycemic control with Prevalence of Microalbuminuria in Diabetic Patients

open access: yesGomal Journal of Medical Sciences, 2012
Background: Microalbuminuria is a renal marker of generalized vascular endothelial damage and early atherosclerosis. Patients with microalbuminuria are at increased risk of microvascular and macrovascular complications of diabetes mellitus like ...
Purdil Khan   +4 more
doaj  

Association of microalbuminuria with metabolic syndrome: a cross-sectional study in Bangladesh

open access: yesBMC Endocrine Disorders, 2020
Background and aims The objectives of this study were to estimate the prevalence of microalbuminuria and examine the association of microalbuminuria with metabolic syndrome (MetS) and its component in a Bangladeshi adult cohort.
Muntakim Mahmud Saadi   +5 more
doaj   +1 more source

Dental amalgam fillings: An under-investigated source of mercury exposure [PDF]

open access: yes, 2019
Dental amalgam fillings, which contain about 50% mercury, have been used since the early 19th century. However, their use has been controversial, particularly because they continually release small amounts of mercury.
Ahlqwist   +55 more
core   +1 more source

Diabetic kidney disease, biomarkers, and finerenone

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Diabetic kidney disease (DKD), the leading cause of kidney failure worldwide, is associated with an increased risk of cardiovascular disease (CVD). A complex pathobiology involving hemodynamic, metabolic, and immune dysregulation promotes inflammatory and fibrotic pathways that contribute to kidney disease progression and CVD in individuals ...
Ashish Verma, Ashish Upadhyay
wiley   +1 more source

Effect of empagliflozin on urinary albumin excretion and hypoxic biomarkers in early diabetic kidney disease: A randomised double‐blind, placebo‐controlled trial

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
Abstract Aims The precise mechanism of sodium glucose co‐transporter 2 (SGLT2) inhibitor on reno‐protective effect has been still unclear. In this study, we hypothesised that SGLT2 inhibitor prevents diabetic kidney disease via reduction of hypoxia‐induced factors.
Hisashi Makino   +14 more
wiley   +1 more source

Evaluating Associations Between Ankylosing Spondylitis, Torque Teno Virus and Polymorphisms in Interleukin 6 and Vitamin D Receptor Genes

open access: yesInternational Journal of Immunogenetics, EarlyView.
ABSTRACT The etiology of ankylosing spondylitis (AS) is complex and not yet fully understood. Interleukin‐6 (IL‐6), vitamin D and the vitamin D receptor (VDR) play an important role in modulating immune response, and Torque teno virus is considered a marker of immune status. This case–control study aimed to investigate the predisposition to AS. A total
Dănuț Cimponeriu   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy